Letairis and Diplopia - a phase IV clinical study of FDA data

Summary:

Diplopia is reported as a side effect among people who take Letairis (ambrisentan), especially for people who are female, 60+ old, have been taking the drug for < 1 month also take Adcirca, and have Systemic sclerosis (scleroderma).

The phase IV clinical study analyzes which people have Diplopia when taking Letairis. It is created by eHealthMe based on reports of 93,991 people who have side effects when taking Letairis from the FDA, and is updated regularly.

What is Letairis?

Letairis has active ingredients of ambrisentan. It is often used in pulmonary hypertension. eHealthMe is studying from 94,041 Letairis users. Check the latest studies of Letairis.

What is Diplopia?

Diplopia (double vision) is found to be associated with 1,427 drugs and 1,895 conditions by eHealthMe. Check the latest studies of Diplopia.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Sep, 01, 2026

93,991 people reported to have side effects when taking Letairis.
Among them, 53 people (0.06%) have Diplopia.

Among these 53 people:

How long have people been on Letairis when they have Diplopia? *

What is the gender of people who have Diplopia when taking Letairis? *

female: 79.25 %
male: 20.75 %

What is the age of people who have Diplopia when taking Letairis? *

What are other drugs people take besides Letairis? *

What are other side effects people have besides Diplopia? *

Vision Blurred: 14 people, 26.42%
Dyspnea (difficult or laboured breathing): 12 people, 22.64%
Diarrhea: 11 people, 20.75%
Headache (pain in head): 11 people, 20.75%
Nausea (feeling of having an urge to vomit): 9 people, 16.98%
Dizziness: 9 people, 16.98%
Pain In Jaw: 8 people, 15.09%
Fatigue (feeling of tiredness): 7 people, 13.21%
Fluid Retention (an abnormal accumulation of fluid in the blood): 6 people, 11.32%
Drug Intolerance (drug sensitivity): 6 people, 11.32%

What are the existing conditions these people have? *

Systemic Sclerosis (Scleroderma) (an autoimmune or connective tissue disease. it is characterized by thickening of the skin): 3 people, 5.66%
Sarcoidosis (an inflammatory disease that affects multiple organs in the body, but mostly the lungs and lymph glands): 2 people, 3.77%
Lower Respiratory Tract Infection: 1 person, 1.89%
Bladder Irritation: 1 person, 1.89%
Complex Partial Seizures (epileptic seizure): 1 person, 1.89%
Connective Tissue Disorder (any disease that has the connective tissues of the body): 1 person, 1.89%
Cor Pulmonale Chronic (long lasting enlargement of the right ventricle of the heart): 1 person, 1.89%
Crohn's Disease (a condition that causes inflammation of the gastrointestinal tract): 1 person, 1.89%
Depression: 1 person, 1.89%
Hepatic Cirrhosis (chronic liver disease characterized by replacement of liver tissue by fibrosis, scar tissue): 1 person, 1.89%

* Approximation only. Some reports may have incomplete information.

Do you take Letairis and have Diplopia?

- Check whether Diplopia is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Letairis:

Letairis (94,041 reports)

Diplopia treatments and more:

Diplopia (32,466 reports)

Browse all side effects of Letairis:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Diplopia:

Diplopia (1,427 drugs)

Browse all the conditions that are associated with Diplopia:

Diplopia (1,895 conditions)

Related publications that referenced our studies

Kocamaz, M., & Karadag, O., "Topiramate-Induced Acute Myopia, Diplopia, and Photosensitivity: A Case Report", Beyoglu Eye Journal, 2019 Jan .
Kocamaz, M., & Karadag, O., "Topiramate-Induced Acute Myopia, Diplopia, and Photosensitivity: A Case Report", Beyoglu Eye Journal, 2019 Jan .

How the study uses the data?

The study uses data from the FDA. It is based on ambrisentan (the active ingredients of Letairis) and Letairis (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.